Wolfe Kelly, Peyvandi Shabnam
Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Department of Pediatrics, UCSF Benioff Children's Hospital. Oakland, California, USA.
Curr Opin Cardiol. 2025 Jul 1;40(4):259-264. doi: 10.1097/HCO.0000000000001218. Epub 2025 May 13.
Neurodevelopmental impairments are the most common comorbidity among children, adolescents, and adults with congenital heart disease (CHD). Despite significant advances in operative and perioperative care resulting in increased survival, neurodevelopmental impairments remain prevalent in this population. Neurodevelopmental impairments, though subtle, can have a major impact on quality of life, attainment of independence and societal contribution. In this review, we summarize current knowledge on neurodevelopmental outcomes in the CHD population, including neuroimaging findings, known risk factors and opportunities to optimize outcomes.
Several risk factors have been identified contributing to neurodevelopmental impairments across the lifespan. These include risk factors originating in the prenatal period and new risk factors that are acquired in adulthood. The risk factors encompass several categories, including genetic abnormalities, aberrant cardiovascular physiology, environmental factors, social determinants of health and mental health. Many risk factors can be considered modifiable, though large multicenter studies identifying the most salient risk factors for neurodevelopmental impairment are lacking.
In this review, we identify potentially modifiable risk factors for neurodevelopmental impairment in the CHD population that can be studies in future neuroprotective clinical trials.
神经发育障碍是先天性心脏病(CHD)儿童、青少年和成人中最常见的合并症。尽管手术和围手术期护理取得了显著进展,提高了生存率,但神经发育障碍在这一人群中仍然普遍存在。神经发育障碍虽然细微,但会对生活质量、独立能力的获得和社会贡献产生重大影响。在本综述中,我们总结了目前关于CHD人群神经发育结局的知识,包括神经影像学发现、已知的风险因素以及优化结局的机会。
已确定了几个导致全生命周期神经发育障碍的风险因素。这些因素包括起源于产前时期的风险因素以及成年期出现的新风险因素。风险因素涵盖多个类别,包括基因异常、异常的心血管生理学、环境因素、健康的社会决定因素和心理健康。许多风险因素可被视为可改变的,不过缺乏确定神经发育障碍最显著风险因素的大型多中心研究。
在本综述中,我们确定了CHD人群中神经发育障碍的潜在可改变风险因素,这些因素可在未来的神经保护临床试验中进行研究。